Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved]
Background This study investigates the incidence and predictive factors of Hyperventilation Syndrome (HVS) in patients after COVID 19 pneumonia, addressing the clinical overlap between these conditions. Methods A one-month prospective study was conducted, tracking survivors of COVID-19 pneumonia. Pa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2024-12-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/13-1497/v1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725879043751936 |
|---|---|
| author | Salma Mokaddem Hela CHERIF Mohamed Ridha Charfi Ferdaous Yangui Slim Kalboussi Soumaya Debiche |
| author_facet | Salma Mokaddem Hela CHERIF Mohamed Ridha Charfi Ferdaous Yangui Slim Kalboussi Soumaya Debiche |
| author_sort | Salma Mokaddem |
| collection | DOAJ |
| description | Background This study investigates the incidence and predictive factors of Hyperventilation Syndrome (HVS) in patients after COVID 19 pneumonia, addressing the clinical overlap between these conditions. Methods A one-month prospective study was conducted, tracking survivors of COVID-19 pneumonia. Patients were evaluated for ongoing clinical status, including HVS and post-traumatic syndrome disorder (PTSD), using clinical questionnaires, mMRC, Post-COVID-19 Functional Status (PCFS) Score, Nijmegen score, and PTSD Checklist for DSM-5 questionnaire. Results Our study included 222 patients (median age: 57 years, male predominance 62.6%). Somatic comorbidities, primarily metabolic disorders, were reported in 71.2% of cases. The majority had severe or critical infection forms (78.4%), and 91.9% experienced acute symptoms, with 86.5% having three or more symptom clusters. At one month follow-up, dyspnea (52.9%) and asthenia (21.7%) persisted. Functional limitations (PCFS Grade > 2) were observed in 19.6% of patients. The overall incidence of HVS was 158 per 1000 patients, and PTSD was 445 per 1000 patients. Multivariate logistic regression identified cognitive impairment (acute phase), persistent weight loss (post-COVID-19 phase), PCFS grade > 2, and PTSD as independent factors for developing HVS, with relative risks (RRs) of 3.47 (95%CI [1.48-8.31]; p = 0.004), 11.87 (95%CI [1.25-112.88]; p = 0.031), 3.24 (95%CI [1.34-7.86]; p = 0.009), and 5.98 (95%CI [2.27-15.77]; p < 0.001), respectively. Conclusion HVS is prevalent in the post-COVID-19 phase, affecting 15.6 % of survivors. Identified predictive factors suggest the convergence of psychosomatic pathophysiological mechanisms. Further research is crucial for a detailed understanding of these mechanisms in long COVID-19 patients. |
| format | Article |
| id | doaj-art-1bfbd590175a402da9957dc146e79c10 |
| institution | DOAJ |
| issn | 2046-1402 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj-art-1bfbd590175a402da9957dc146e79c102025-08-20T03:10:21ZengF1000 Research LtdF1000Research2046-14022024-12-011310.12688/f1000research.152196.1166928Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved]Salma Mokaddem0https://orcid.org/0000-0002-7775-3073Hela CHERIF1https://orcid.org/0000-0002-2086-918XMohamed Ridha Charfi2Ferdaous Yangui3https://orcid.org/0000-0003-2465-0019Slim Kalboussi4Soumaya Debiche5https://orcid.org/0009-0003-9211-3095Pulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaPulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaPulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaPulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaPulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaPulmonology Department, Internal Security Forces Hospital, Tunis, TunisiaBackground This study investigates the incidence and predictive factors of Hyperventilation Syndrome (HVS) in patients after COVID 19 pneumonia, addressing the clinical overlap between these conditions. Methods A one-month prospective study was conducted, tracking survivors of COVID-19 pneumonia. Patients were evaluated for ongoing clinical status, including HVS and post-traumatic syndrome disorder (PTSD), using clinical questionnaires, mMRC, Post-COVID-19 Functional Status (PCFS) Score, Nijmegen score, and PTSD Checklist for DSM-5 questionnaire. Results Our study included 222 patients (median age: 57 years, male predominance 62.6%). Somatic comorbidities, primarily metabolic disorders, were reported in 71.2% of cases. The majority had severe or critical infection forms (78.4%), and 91.9% experienced acute symptoms, with 86.5% having three or more symptom clusters. At one month follow-up, dyspnea (52.9%) and asthenia (21.7%) persisted. Functional limitations (PCFS Grade > 2) were observed in 19.6% of patients. The overall incidence of HVS was 158 per 1000 patients, and PTSD was 445 per 1000 patients. Multivariate logistic regression identified cognitive impairment (acute phase), persistent weight loss (post-COVID-19 phase), PCFS grade > 2, and PTSD as independent factors for developing HVS, with relative risks (RRs) of 3.47 (95%CI [1.48-8.31]; p = 0.004), 11.87 (95%CI [1.25-112.88]; p = 0.031), 3.24 (95%CI [1.34-7.86]; p = 0.009), and 5.98 (95%CI [2.27-15.77]; p < 0.001), respectively. Conclusion HVS is prevalent in the post-COVID-19 phase, affecting 15.6 % of survivors. Identified predictive factors suggest the convergence of psychosomatic pathophysiological mechanisms. Further research is crucial for a detailed understanding of these mechanisms in long COVID-19 patients.https://f1000research.com/articles/13-1497/v1Hyperventilation Syndrome; COVID-19 pneumonia; Post-Traumatic Stress Disorder; Prospective Studies; Incidenceeng |
| spellingShingle | Salma Mokaddem Hela CHERIF Mohamed Ridha Charfi Ferdaous Yangui Slim Kalboussi Soumaya Debiche Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] F1000Research Hyperventilation Syndrome; COVID-19 pneumonia; Post-Traumatic Stress Disorder; Prospective Studies; Incidence eng |
| title | Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] |
| title_full | Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] |
| title_fullStr | Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] |
| title_full_unstemmed | Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] |
| title_short | Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study [version 1; peer review: 2 approved] |
| title_sort | incidence and predictive factors of hyperventilation syndrome in patients after covid 19 pneumonia a prospective cohort study version 1 peer review 2 approved |
| topic | Hyperventilation Syndrome; COVID-19 pneumonia; Post-Traumatic Stress Disorder; Prospective Studies; Incidence eng |
| url | https://f1000research.com/articles/13-1497/v1 |
| work_keys_str_mv | AT salmamokaddem incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved AT helacherif incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved AT mohamedridhacharfi incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved AT ferdaousyangui incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved AT slimkalboussi incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved AT soumayadebiche incidenceandpredictivefactorsofhyperventilationsyndromeinpatientsaftercovid19pneumoniaaprospectivecohortstudyversion1peerreview2approved |